Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00

Giancarlo Pruneri, Kathryn P. Gray, Andrea Vingiani, Giuseppe Viale, Giuseppe Curigliano, Carmen Criscitiello, István Láng, Thomas Ruhstaller, Lorenzo Gianni, Aron Goldhirsch, Roswitha Kammler, Karen N. Price, Giuseppe Cancello, Elisabetta Munzone, Richard D. Gelber, Meredith M. Regan, Marco Colleoni

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

The purpose of this study was to assess the prognostic and predictive value of tumor-infiltrating lymphocytes (TILs) in the triple-negative breast cancer (TNBC) cohort of the phase III IBCSG trial 22-00, comparing low-dose oral ‘metronomic’ cyclophosphamide-methotrexate maintenance chemotherapy (CM-maintenance) to no-CM-maintenance in early breast cancer. TILs were evaluated in full-face hematoxylin-and-eosin-stained sections of tumor samples confirmed centrally as TNBC (

Original languageEnglish
Pages (from-to)323-331
Number of pages9
JournalBreast Cancer Research and Treatment
Volume158
Issue number2
DOIs
Publication statusPublished - Jul 1 2016

    Fingerprint

Keywords

  • Breast cancer
  • Low-dose maintenance chemotherapy
  • Prognosis
  • Triple negative
  • Tumor-infiltrating lymphocytes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Pruneri, G., Gray, K. P., Vingiani, A., Viale, G., Curigliano, G., Criscitiello, C., Láng, I., Ruhstaller, T., Gianni, L., Goldhirsch, A., Kammler, R., Price, K. N., Cancello, G., Munzone, E., Gelber, R. D., Regan, M. M., & Colleoni, M. (2016). Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. Breast Cancer Research and Treatment, 158(2), 323-331. https://doi.org/10.1007/s10549-016-3863-3